Arkansas Awarded $1.5 Million in Multi-State Settlement
By: News Release
Updated: November 19, 2012
Attorney General Dustin McDaniel announced on Monday that he and 37 other attorneys general have reached a $90 million settlement with GlaxoSmithKline LLC to resolve allegations that the pharmaceutical manufacturer unlawfully promoted its diabetes drug, Avandia.
McDaniel filed a consent judgment in Pulaski County Circuit Court last week, settling claims that GlaxoSmithKline illegally marketed Avandia by misrepresenting its safety risks related to heart attacks and strokes.
Arkansas's portion of the settlement is $1,557,495.30.
"Any time drug companies mislead the public, our office will work to ensure the companies are held responsible for their wrongdoing," McDaniel said. "It is my hope that this result sends a strong message to any company about the importance of providing Arkansas physicians and consumers with accurate information about its products."
As part of the settlement, GlaxoSmithKline will be barred from making false, misleading or deceptive claims about any diabetes drugs. Claims about the safety of its drugs compared to others must be supported by substantial evidence or clinical experience. GSK must also make available to the public summaries of the results of all studies of its diabetes drugs.
McDaniel filed a consent judgment in Pulaski County Circuit Court last week, settling claims that GlaxoSmithKline illegally marketed Avandia by misrepresenting its safety risks related to heart attacks and strokes.
Arkansas's portion of the settlement is $1,557,495.30.
"Any time drug companies mislead the public, our office will work to ensure the companies are held responsible for their wrongdoing," McDaniel said. "It is my hope that this result sends a strong message to any company about the importance of providing Arkansas physicians and consumers with accurate information about its products."
As part of the settlement, GlaxoSmithKline will be barred from making false, misleading or deceptive claims about any diabetes drugs. Claims about the safety of its drugs compared to others must be supported by substantial evidence or clinical experience. GSK must also make available to the public summaries of the results of all studies of its diabetes drugs.
